BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gantier MP, Tong S, Behlke MA, Irving AT, Lappas M, Nilsson UW, Latz E, McMillan NA, Williams BR. Rational design of immunostimulatory siRNAs. Mol Ther 2010;18:785-95. [PMID: 20125126 DOI: 10.1038/mt.2010.4] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Kusiak A, Brady G. Bifurcation of signalling in human innate immune pathways to NF-kB and IRF family activation. Biochem Pharmacol 2022;205:115246. [PMID: 36088989 DOI: 10.1016/j.bcp.2022.115246] [Reference Citation Analysis]
2 Brown GJ, Cañete PF, Wang H, Medhavy A, Bones J, Roco JA, He Y, Qin Y, Cappello J, Ellyard JI, Bassett K, Shen Q, Burgio G, Zhang Y, Turnbull C, Meng X, Wu P, Cho E, Miosge LA, Andrews TD, Field MA, Tvorogov D, Lopez AF, Babon JJ, López CA, Gónzalez-Murillo Á, Garulo DC, Pascual V, Levy T, Mallack EJ, Calame DG, Lotze T, Lupski JR, Ding H, Ullah TR, Walters GD, Koina ME, Cook MC, Shen N, de Lucas Collantes C, Corry B, Gantier MP, Athanasopoulos V, Vinuesa CG. TLR7 gain-of-function genetic variation causes human lupus. Nature 2022;605:349-56. [PMID: 35477763 DOI: 10.1038/s41586-022-04642-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 23.0] [Reference Citation Analysis]
3 Lan T, Wei Z, He Y, Wan S, Liu L, Cheng B, Li R, Chen H, Liu G, Meng Z. Immunostimulatory siRNA with a uridine bulge leads to potent inhibition of HBV and activation of innate immunity. Virol J 2021;18:37. [PMID: 33602251 DOI: 10.1186/s12985-021-01509-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Alharbi AS, Garcin AJ, Lennox KA, Pradeloux S, Wong C, Straub S, Valentin R, Pépin G, Li HM, Nold MF, Nold-Petry CA, Behlke MA, Gantier MP. Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists. Nucleic Acids Res 2020;48:7052-65. [PMID: 32544249 DOI: 10.1093/nar/gkaa523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. Cancer Immunol Immunother 2020;69:2465-76. [PMID: 32556443 DOI: 10.1007/s00262-020-02634-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu S, Jaouannet M, Dempsey DA, Imani J, Coustau C, Kogel K. RNA-based technologies for insect control in plant production. Biotechnology Advances 2020;39:107463. [DOI: 10.1016/j.biotechadv.2019.107463] [Cited by in Crossref: 85] [Cited by in F6Publishing: 60] [Article Influence: 42.5] [Reference Citation Analysis]
7 Bajan S, Hutvagner G. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. Cells 2020;9:E137. [PMID: 31936122 DOI: 10.3390/cells9010137] [Cited by in Crossref: 167] [Cited by in F6Publishing: 171] [Article Influence: 83.5] [Reference Citation Analysis]
8 Hardy MP, Audemard É, Migneault F, Feghaly A, Brochu S, Gendron P, Boilard É, Major F, Dieudé M, Hébert MJ, Perreault C. Apoptotic endothelial cells release small extracellular vesicles loaded with immunostimulatory viral-like RNAs. Sci Rep 2019;9:7203. [PMID: 31076589 DOI: 10.1038/s41598-019-43591-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
9 Maroof H, Islam F, Dong L, Ajjikuttira P, Gopalan V, McMillan NAJ, Lam AK. Liposomal Delivery of miR-34b-5p Induced Cancer Cell Death in Thyroid Carcinoma. Cells 2018;7:E265. [PMID: 30544959 DOI: 10.3390/cells7120265] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
10 Nagpal G, Chaudhary K, Dhanda SK, Raghava GPS. Computational Prediction of the Immunomodulatory Potential of RNA Sequences. Methods Mol Biol 2017;1632:75-90. [PMID: 28730433 DOI: 10.1007/978-1-4939-7138-1_5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
11 Meng Z, Lu M. RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant? Front Immunol 2017;8:331. [PMID: 28386261 DOI: 10.3389/fimmu.2017.00331] [Cited by in Crossref: 87] [Cited by in F6Publishing: 97] [Article Influence: 17.4] [Reference Citation Analysis]
12 Jasinski D, Haque F, Binzel DW, Guo P. Advancement of the Emerging Field of RNA Nanotechnology. ACS Nano 2017;11:1142-64. [PMID: 28045501 DOI: 10.1021/acsnano.6b05737] [Cited by in Crossref: 210] [Cited by in F6Publishing: 179] [Article Influence: 42.0] [Reference Citation Analysis]
13 Antimisiaris S, Mourtas S, Papadia K. Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential. Int J Pharm 2017;525:293-312. [PMID: 28163221 DOI: 10.1016/j.ijpharm.2017.01.056] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
14 Younis H, Templin M, Whiteley L, Kornbrust D, Kim T, Henry S. Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics. A Comprehensive Guide to Toxicology in Nonclinical Drug Development 2017. [DOI: 10.1016/b978-0-12-803620-4.00028-1] [Reference Citation Analysis]
15 Ferrand J, Gantier MP. Assessing the Inhibitory Activity of Oligonucleotides on TLR7 Sensing. Methods Mol Biol 2016;1390:79-90. [PMID: 26803623 DOI: 10.1007/978-1-4939-3335-8_5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
16 Ohno S, Itano K, Harada Y, Asada K, Oikawa K, Kashiwazako M, Okuyama H, Kumagai K, Takanashi M, Sudo K, Ikeda N, Kuroda M. Development of Novel Small Hairpin RNAs That do not Require Processing by Dicer or AGO2. Mol Ther 2016;24:1278-89. [PMID: 27109632 DOI: 10.1038/mt.2016.81] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
17 Wang T, Shigdar S, Shamaileh HA, Gantier MP, Yin W, Xiang D, Wang L, Zhou SF, Hou Y, Wang P, Zhang W, Pu C, Duan W. Challenges and opportunities for siRNA-based cancer treatment. Cancer Lett. 2017;387:77-83. [PMID: 27045474 DOI: 10.1016/j.canlet.2016.03.045] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 9.7] [Reference Citation Analysis]
18 Lebold KM, Jacoby DB, Drake MG. Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease. Transfus Med Hemother 2016;43:114-9. [PMID: 27226793 DOI: 10.1159/000445324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
19 Kabilova TO, Sen'kova AV, Nikolin VP, Popova NA, Zenkova MA, Vlassov VV, Chernolovskaya EL. Antitumor and Antimetastatic Effect of Small Immunostimulatory RNA against B16 Melanoma in Mice. PLoS One 2016;11:e0150751. [PMID: 26981617 DOI: 10.1371/journal.pone.0150751] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
20 Chaudhary K, Nagpal G, Dhanda SK, Raghava GP. Prediction of Immunomodulatory potential of an RNA sequence for designing non-toxic siRNAs and RNA-based vaccine adjuvants. Sci Rep 2016;6:20678. [PMID: 26861761 DOI: 10.1038/srep20678] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
21 Alagia A, Eritja R. siRNA and RNAi optimization. Wiley Interdiscip Rev RNA 2016;7:316-29. [PMID: 26840434 DOI: 10.1002/wrna.1337] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
22 Wang T, Gantier MP, Xiang D, Bean AG, Bruce M, Zhou SF, Khasraw M, Ward A, Wang L, Wei MQ, AlShamaileh H, Chen L, She X, Lin J, Kong L, Shigdar S, Duan W. EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Theranostics 2015;5:1456-72. [PMID: 26681989 DOI: 10.7150/thno.11692] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 9.3] [Reference Citation Analysis]
23 Rodrigues AF, Soares HR, Guerreiro MR, Alves PM, Coroadinha AS. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology. Biotechnol J 2015;10:1329-44. [PMID: 26212697 DOI: 10.1002/biot.201400387] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
24 Sita TL, Stegh AH. Nanoparticle Conjugates for Small Interfering RNA Delivery. Reviews in Cell Biology and Molecular Medicine 2015. [DOI: 10.1002/3527600906.mcb.201500006] [Reference Citation Analysis]
25 Sarvestani ST, Stunden HJ, Behlke MA, Forster SC, McCoy CE, Tate MD, Ferrand J, Lennox KA, Latz E, Williams BR, Gantier MP. Sequence-dependent off-target inhibition of TLR7/8 sensing by synthetic microRNA inhibitors. Nucleic Acids Res 2015;43:1177-88. [PMID: 25539920 DOI: 10.1093/nar/gku1343] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
26 Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol 2014;14:546-58. [PMID: 25060580 DOI: 10.1038/nri3713] [Cited by in Crossref: 502] [Cited by in F6Publishing: 524] [Article Influence: 62.8] [Reference Citation Analysis]
27 Barik S, Bitko V. Emerging Clinical Applications and Pharmacology of RNA. Encyclopedia of Molecular Cell Biology and Molecular Medicine 2014. [DOI: 10.1002/3527600906.mcb.200400102.pub3] [Reference Citation Analysis]
28 Sajeesh S, Lee TY, Hong SW, Dua P, Choe JY, Kang A, Yun WS, Song C, Park SH, Kim S, Li C, Lee D. Long dsRNA-Mediated RNA Interference and Immunostimulation: A Targeted Delivery Approach Using Polyethyleneimine Based Nano-Carriers. Mol Pharmaceutics 2014;11:872-84. [DOI: 10.1021/mp400541z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
29 Swaminathan S, Murray DD, Kelleher AD. miRNAs and HIV: unforeseen determinants of host-pathogen interaction. Immunol Rev 2013;254:265-80. [PMID: 23772625 DOI: 10.1111/imr.12077] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
30 Hinton TM, Challagulla A, Stewart CR, Guerrero-Sanchez C, Grusche FA, Shi S, Bean AG, Monaghan P, Gunatillake PA, Thang SH, Tizard ML. Inhibition of influenza virus in vivo by siRNA delivered using ABA triblock copolymer synthesized by reversible addition-fragmentation chain-transfer polymerization. Nanomedicine (Lond) 2014;9:1141-54. [PMID: 24364874 DOI: 10.2217/nnm.13.119] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
31 Sarvestani ST, Tate MD, Moffat JM, Jacobi AM, Behlke MA, Miller AR, Beckham SA, McCoy CE, Chen W, Mintern JD, O'Keeffe M, John M, Williams BR, Gantier MP. Inosine-mediated modulation of RNA sensing by Toll-like receptor 7 (TLR7) and TLR8. J Virol 2014;88:799-810. [PMID: 24227841 DOI: 10.1128/JVI.01571-13] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
32 Corbeau P. RNAi Gene Therapy to Combat HIV-1 Infection. Encyclopedia of Molecular Cell Biology and Molecular Medicine 2013. [DOI: 10.1002/3527600906.mcb.201200029] [Reference Citation Analysis]
33 Sui H, Zhou M, Chen Q, Lane HC, Imamichi T. siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway. Nucleic Acids Res 2014;42:583-98. [PMID: 24049081 DOI: 10.1093/nar/gkt844] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
34 Lan P, Zhang C, Han Q, Zhang J, Tian Z. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology 2013;58:73-85. [PMID: 23447417 DOI: 10.1002/hep.26339] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
35 Gantier MP. Strategies for designing and validating immunostimulatory siRNAs. Methods Mol Biol 2013;942:179-91. [PMID: 23027052 DOI: 10.1007/978-1-62703-119-6_10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
36 Younis HS, Templin M, Whitely LO, Kornbrust D, Kim T, Henry SP. Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics. A Comprehensive Guide to Toxicology in Preclinical Drug Development. Elsevier; 2013. pp. 647-64. [DOI: 10.1016/b978-0-12-387815-1.00026-5] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 Zhou C, Chattopadhyaya J. Challenges in the Chemistry of Small Interfering RNA as Potential Therapeutics to Inhibit Cellular mRNA Expression. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering 2013. [DOI: 10.1016/b978-0-12-409547-2.05337-3] [Reference Citation Analysis]
38 Singhania R, Khairuddin N, Clarke D, McMillan NA. RNA interference for the treatment of papillomavirus disease. Open Virol J 2012;6:204-15. [PMID: 23341856 DOI: 10.2174/1874357901206010204] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
39 Malhotra M, Nambiar S, Rengaswamy V, Prakash S. Small interfering ribonucleic acid design strategies for effective targeting and gene silencing. Expert Opin Drug Discov 2011;6:269-89. [PMID: 22647204 DOI: 10.1517/17460441.2011.555394] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
40 Sarvestani ST, Williams BR, Gantier MP. Human Toll-like receptor 8 can be cool too: implications for foreign RNA sensing. J Interferon Cytokine Res 2012;32:350-61. [PMID: 22817608 DOI: 10.1089/jir.2012.0014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
41 Glebova KV, Marakhonov AV, Baranova AV, Skoblov MY. Therapeutic siRNAs and nonviral systems for their delivery. Mol Biol 2012;46:335-48. [DOI: 10.1134/s0026893312020069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Dalpke A, Helm M. RNA mediated Toll-like receptor stimulation in health and disease. RNA Biol 2012;9:828-42. [PMID: 22617878 DOI: 10.4161/rna.20206] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
43 Barik S, Bitko V. Emerging Clinical Applications and Pharmacology of RNA. Encyclopedia of Molecular Cell Biology and Molecular Medicine 2012. [DOI: 10.1002/3527600906.mcb.200400102.pub2] [Reference Citation Analysis]
44 Durfort T, Tkach M, Meschaninova MI, Rivas MA, Elizalde PV, Venyaminova AG, Schillaci R, François JC. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model. PLoS One 2012;7:e29213. [PMID: 22235273 DOI: 10.1371/journal.pone.0029213] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
45 Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012;226:365-379. [PMID: 22069063 DOI: 10.1002/path.2993] [Cited by in Crossref: 281] [Cited by in F6Publishing: 289] [Article Influence: 25.5] [Reference Citation Analysis]
46 Chang CI, Kim HA, Dua P, Kim S, Li CJ, Lee DK. Structural diversity repertoire of gene silencing small interfering RNAs. Nucleic Acid Ther 2011;21:125-31. [PMID: 21749289 DOI: 10.1089/nat.2011.0286] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
47 Du Q, Huang H, Liang Z. siRNA: The Specificity and off-Target Effects. Medicinal Chemistry of Nucleic Acids 2011. [DOI: 10.1002/9781118092804.ch12] [Reference Citation Analysis]
48 Stewart CR, Karpala AJ, Lowther S, Lowenthal JW, Bean AG. Immunostimulatory motifs enhance antiviral siRNAs targeting highly pathogenic avian influenza H5N1. PLoS One 2011;6:e21552. [PMID: 21747939 DOI: 10.1371/journal.pone.0021552] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
49 Dua P, Yoo JW, Kim S, Lee DK. Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing. Mol Ther 2011;19:1676-87. [PMID: 21673662 DOI: 10.1038/mt.2011.109] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
50 Chang CI, Lee TY, Dua P, Kim S, Li CJ, Lee D. Long Double-Stranded RNA-Mediated RNA Interference and Immunostimulation: Long Interfering Double-Stranded RNA as a Potent Anticancer Therapeutics. Nucleic Acid Therapeutics 2011;21:149-55. [DOI: 10.1089/nat.2011.0296] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
51 Chang CI, Kim HA, Dua P, Kim S, Li CJ, Lee D. Structural Diversity Repertoire of Gene Silencing Small Interfering RNAs. Oligonucleotides 2011. [DOI: 10.1089/oli.2011.0286] [Reference Citation Analysis]
52 Gantier MP, McCoy CE, Rusinova I, Saulep D, Wang D, Xu D, Irving AT, Behlke MA, Hertzog PJ, Mackay F. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res. 2011;39:5692-5703. [PMID: 21447562 DOI: 10.1093/nar/gkr148] [Cited by in Crossref: 289] [Cited by in F6Publishing: 299] [Article Influence: 26.3] [Reference Citation Analysis]
53 Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol 2012;90:187-96. [PMID: 21423261 DOI: 10.1038/icb.2011.19] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
54 De Rosa G, De Stefano D, Galeone A. Oligonucleotide delivery in cancer therapy. Expert Opin Drug Deliv 2010;7:1263-78. [PMID: 20977291 DOI: 10.1517/17425247.2010.527942] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
55 Peacock H, Fostvedt E, Beal PA. Minor-groove-modulating adenosine replacements control protein binding and RNAi activity in siRNAs. ACS Chem Biol 2010;5:1115-24. [PMID: 20863128 DOI: 10.1021/cb100245u] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
56 Gantier MP, Irving AT, Kaparakis-Liaskos M, Xu D, Evans VA, Cameron PU, Bourne JA, Ferrero RL, John M, Behlke MA, Williams BR. Genetic modulation of TLR8 response following bacterial phagocytosis. Hum Mutat 2010;31:1069-79. [PMID: 20652908 DOI: 10.1002/humu.21321] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
57 Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 2010;28:570-579. [PMID: 20833440 DOI: 10.1016/j.tibtech.2010.07.009] [Cited by in Crossref: 208] [Cited by in F6Publishing: 220] [Article Influence: 17.3] [Reference Citation Analysis]
58 Barik S. siRNA for Influenza Therapy. Viruses 2010;2:1448-57. [PMID: 21994689 DOI: 10.3390/v2071448] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]